MEDIA

MEDIA - NEWS AND UPCOMING EVENTS

Media Contact:

Julie A. Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca  416-951-7988

NEWS ARCHIVES

All Articles

Interface Biologics Announces New V.P., Business Development
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the addition of Kelley Dealhoy, to the IBI management team, as Vice President of Business Development.
Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce a positive pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases.
Paul Santerre named Baxter Chair of Health Technology and Commercialization
U of T professor Paul Santerre (Dentistry, IBBME) has been named the Baxter Chair of Health Technology and Commercialization. Created through a $2.5-million investment from the Baxter Corporation to the University Health Network (UHN), the chair will enable Santerre to drive commercialization and entrepreneurship initiatives at both UHN and U of T.
Interface Biologics Enters the Neurology Market with 510(k) Clearance of Arkis BioSciences® CerebroFlo™ EVD Catheter with Endexo® Technology
Interface Biologics Inc. ("IBI"), a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.
Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study published in CMAJ open
AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the publication of a nurse-led, peripherally inserted central catheter (PICC) study in the July 4, 2017 edition of CMAJ Open, an online medical and health research journal of the Canadian Medical Association.
U of T inventor-entrepreneur honoured with Governor General’s Innovation Award
The molecules he works with are so small they can’t be seen with the naked eye, but for Professor Paul Santerre, who is being honoured with the 2017 Governor General’s Innovation Award, it’s what you do with those molecules that counts. One of six awardees to be recognized at a special ceremony at Rideau Hall on May 23, Santerre’s award recognizes his sweeping entrepreneurial vision for scientific inquiry — and its vital role in shaping Canada’s innovation economy.
Interface Biologics Announces New V.P., R&D
TORONTO, Canada, September 13, 2016 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of transformative biomedical-polymer technologies that improve the safety and effectiveness of medical devices, is pleased to announce the
Medical device clears regulatory hurdle in the United States
September 17, 2012 – What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.
Paul Santerre: making medical devices safer and better
February 27, 2013 - Professor Paul Santerre began his career at the University in 1993 in the Faculty of Dentistry and is a member of the Centre for Biomaterials, where he has conducted research into biomaterials - molecules and polymers designed to inter
Interface Biologics Appoints Dion Madsen to Board of Directors
Toronto, ON, Canada, May 12, 2014 -- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Dion Madsen to the Board of Directors. Mr. Madsen is
Tom Reeves is an EY Entrepreneur Of The Year 2014 award finalist
Toronto, ON, Canada, July 7, 2014 -- EY is pleased to announce this year’s gravity-defying Entrepreneur Of The Year finalists in Ontario. “This year’s finalists prove that the future of entrepreneurship in our country is brighter than ever,” says Colleen
Saluting Ontario’s gravity-defying entrepreneurs
Tom Reeves leads the team of scientists and engineers at Interface Biologics - a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. See pg
AngioDynamics Begins Shipment of New Midline Catheters
AngioDynamics a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the launch of the BioFlo Midline catheter indicated for short-term intravenous thera
Interface Biologics Announces New VP Finance
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.
Interface Biologics Announces $7M Financing
Toronto, Canada, January 10th, 2011 – For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the completion of a $7M series B financing, le
Interface Biologics - BASF Future Business Collaborate
Toronto, Canada, January 4, 2011 - For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the signing of a joint development agreement with
U of T is helping to create a culture of innovation
Dentistry professor Paul Santerre understands the world of start-up companies. Ten years ago, well before assuming his current role as director of the Institute of Biomaterials and Biomedical Engineering, Santerre discovered a way to control the adverse r
In conversation with Tom Reeves
As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.
Interface Biologics Expands Scientific Advisory Board
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Boar
Antimicrobial-Infused Polymer Demonstrates Backbone
Implants often rely on antimicrobial coatings to prevent infections. But the release of antibacterial agents via diffusion from a biomaterial’s surface may not be the most effective approach for combating biofilm formation on implants. With this in mind,
Powered by Innovasium